Operating
Change in fair value of equity securities
Gilead Sciences Change in fair value of equity securities decreased by 43.9% to $142.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 133.3%, from -$426.00M to $142.00M. Over 2 years (FY 2021 to FY 2025), Change in fair value of equity securities shows an upward trend with a -14.0% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2017
Last reportedQ1 2026May 7, 2026
How to read this metric
An increase reflects unrealized gains in the investment portfolio, while a decrease reflects unrealized losses, impacting reported net income without affecting cash flow.
Detailed definition
This represents the non-cash impact of fluctuations in the market value of equity investments held by the company that a...
Peer comparison
Common among large-cap technology firms with strategic investment arms or venture portfolios.
Metric ID:
amd_change_in_equity_securities_fvniHistorical Data
17 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $174.00M | -$142.00M | -$291.00M | -$96.00M | -$303.00M | -$197.00M | -$61.00M | -$256.00M | -$169.00M | -$14.00M | -$391.00M | -$126.00M | -$426.00M | $142.00M | $482.00M | $253.00M | $142.00M |
| QoQ Change | — | -181.6% | -104.9% | +67.0% | -215.6% | +35.0% | +69.0% | -319.7% | +34.0% | +91.7% | <-999% | +67.8% | -238.1% | +133.3% | +239.4% | -47.5% | -43.9% |
| YoY Change | — | — | — | — | -274.1% | -38.7% | +79.0% | -166.7% | +14.2% | +94.5% | — | — | <-999% | +136.3% | — | +300.8% | +133.3% |
Range-$426.00M – $482.00M
CAGR-5.0%
Avg YoY Growth-266.4%
Median YoY Growth+46.6%
Current Streak2 quarters decline
Change in fair value of equity securities at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's change in fair value of equity securities?
- Gilead Sciences (GILD) reported change in fair value of equity securities of $142.00M in Q1 2026.
- How has Gilead Sciences's change in fair value of equity securities changed year-over-year?
- Gilead Sciences's change in fair value of equity securities increased by 133.3% year-over-year, from -$426.00M to $142.00M.
- What is the long-term trend for Gilead Sciences's change in fair value of equity securities?
- Over 2 years (2021 to 2025), Gilead Sciences's change in fair value of equity securities has grown at a -14.0% compound annual growth rate (CAGR), from -$610.00M to $451.00M.
- What does change in fair value of equity securities mean?
- The non-cash impact of market price changes on the company's equity investment portfolio.